Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.31 |
| ▸ | CCND1 | P24385 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2488026 | 0.84 | P2RX7 (0.32) | ALDH1A1KMT2A | |
| SCHEMBL7974226 | 0.81 | KDM4E (0.44) | ALDH1A1LMNAMAPK1MEN1NPC1 | |
| SCHEMBL8487037 | 0.78 | — | — | |
| SCHEMBL7405031 | 0.75 | MAP3K7 (0.44) | ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL7974225 | 0.73 | APP (0.36) | LMNAALOX5NPC1 | |
| SCHEMBL7978927 | 0.72 | AKR1C3 (0.42) | — | |
| SCHEMBL12489954 | 0.71 | — | — | |
| SCHEMBL7839957 | 0.69 | MAPT (0.48) | ALDH1A1LMNAMEN1NPC1KMT2A | |
| SCHEMBL7839951 | 0.69 | HRH3 (0.34) | MAPK1 | |
| SCHEMBL7375916 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1999005114-A2 | 1H-4(5)-SUBSTITUTED IMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS HISTAMINE H3 RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 1999-02-04 | — | — | WO | disclosed |